



To: The Copenhagen Stock Exchange

**Announcement No. 14 in 2005/06
March 14, 2006**

GRAZAX[®] approved in Sweden

Summary: The Swedish Medical Products Agency has approved ALK-Abelló's A/S' tablet-based immunotherapy, GRAZAX[®], for the treatment of grass pollen allergy. ALK-Abelló will now submit applications for GRAZAX[®] in other European countries using the Mutual Recognition Procedure.

ALK-Abelló A/S's tablet-based immunotherapy, GRAZAX[®], has been approved by the Swedish Medical Products Agency for the treatment of grass pollen allergy.

ALK-Abelló will now submit further applications in other European countries via the Mutual Recognition Procedure. ALK-Abelló still expects GRAZAX[®] to be launched in the first European markets by the end of 2006.

According to the approval, treatment with GRAZAX[®] is recommended to be initiated at least eight weeks prior to the grass pollen season. When initiating treatment, it is recommended that the first tablet is taken under the doctor's supervision. As expected, patients suffering from severe asthma, systemic immune diseases and hypersensitivity towards tablet additives should not be treated with GRAZAX[®].

The approval does not change ALK-Abelló's expectations for the current financial year ending August 31, 2006.

Hørsholm, March 14, 2006
ALK-Abelló A/S

Jens Bager
President and CEO

Contact:

Jens Bager, President and CEO, tel +45 4574 7445.

ALK-Abelló will hold a press conference and analyst meeting on Wednesday March 15 at 11:00 a.m. (CET) at which the approval will be reviewed. The meeting will take place at the company headquarters 6-8 Bøge Allé in Hørsholm.



About GRAZAX®

GRAZAX® combines the well established and documented advantages of immunotherapy with a convenient fast-dissolving tablet formulation. The tablet contains standardised grass allergen extract in daily doses of 75,000 SQ-T. It is placed under the tongue once a day, where it melts in a few seconds. GRAZAX® is a baseline treatment that does not require up-dosing and induces a protective immune response which reduces and potentially halts the allergic reaction to grass pollen.

Treatment with GRAZAX® should be initiated at least eight weeks ahead of a pollen season. It reduces allergy symptoms whilst also reducing the need for ordinary, symptom-relieving allergy medication from the first grass pollen season after initiation of treatment. Immunotherapy is normally carried out over a three-year period in order to achieve a lasting effect after the treatment ends.

GRAZAX® has been studied in the largest clinical trial program ever conducted within allergy immunotherapy comprising six clinical trials and a total of more than 1,700 patients. In October 2005, ALK-Abelló announced the results from the GT-08 study, the latest to demonstrate that GRAZAX® is a convenient, highly effective treatment with a good safety profile. The study also confirms the optimal dose of 75,000 SQ-T.

The GT-08 study showed that, already during the first treatment season, GRAZAX® reduces hay fever symptoms by 30% and at the same time reduces the need for symptom-relieving medication by 38% in addition to placebo (median values are 34% and 53%, respectively).

The patients who receive treatment with GRAZAX® experience an improved quality of life. In a global evaluation of patients' perceptions of efficacy of GRAZAX® treatment compared with previous (untreated) seasons, 82% of patients treated with GRAZAX® reported symptom improvement (feeling 'better' or 'much better'), a 49% increase over the placebo group. The results are statistically highly significant ($p < 0.0001$).

GRAZAX® is a trademark owned by ALK-Abelló A/S.

About ALK-Abelló

All around the world millions of people experience reduced quality of life due to allergy. In Europe and the USA alone, more than 80 million people suffer from grass pollen allergy. ALK-Abelló's immunotherapies treat not only the symptoms of allergy but also the underlying disease – and at the same time prevent asthma. ALK-Abelló is a growing company working with the very latest technology in research, development and production. It is the market leader in allergy immunotherapy in Europe and also commands strong positions in the USA and China. ALK-Abelló is headquartered in Hørsholm, north of Copenhagen, Denmark. The company has more than 1,200 employees and is listed on the Copenhagen Stock Exchange.